SUPN — Supernus Pharmaceuticals, Inc.

Summary of Supernus Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $192.1 million, up from $175.7 million in Q3 2024.
• Net Product Sales: $168.5 million, with collaboration revenues from Zurzuvae at $20.2 million.
• GAAP Net Loss: $45.1 million, or $0.80 per diluted share, compared to a net profit of $38.5 million, or $0.69 per diluted share, in Q3 2024.
• Adjusted Operating Earnings: $41.9 million, down from $67.7 million in Q3 2024.
• Cash Position: Approximately $281 million as of September 30, 2025, down from $454 million at year-end 2024.
• R&D and SG&A Expenses: Combined expenses were $209 million, significantly higher due to acquisition-related costs from the Sage acquisition.

2. Strategic Updates and Business Highlights

• Growth Products: Qelbree, GOCOVRI, Zurzuvae, and Onapgo accounted for 78% of total revenues.
• Onapgo Launch: Generated $6.8 million in net sales, a substantial increase from $1.6 million in Q2 2025. Demand is strong, but supply constraints are impacting the ability to meet this demand.
• Zurzuvae Performance: Collaboration revenue of $20.2 million, with a 150% increase in U.S. sales compared to Q3 2024.
• Qelbree: Experienced 23% growth in prescriptions and 31% growth in net sales year-over-year.
• R&D Pipeline: Advancements in programs SPN-443, SPN-820, and SPN-817 are ongoing, with trials expected to initiate in 2026.

3. Forward Guidance and Outlook

• Revenue Guidance: Updated full-year 2025 revenue guidance to $685 million - $705 million, up from $670 million - $700 million.
• Operating Loss Guidance: Expected to be in the range of $65 million to $75 million, improved from the previous range of $70 million to $80 million.
• Non-GAAP Operating Earnings Guidance: Revised to $125 million - $145 million, up from $105 million - $135 million.

4. Bad News, Challenges, or Points of Concern

• Supply Constraints: Onapgo faces supply issues, limiting the ability to meet demand and potentially leading to lost business to competitors.
• Increased Expenses: R&D and SG&A expenses have risen significantly due to acquisition-related costs, impacting overall profitability.
• GAAP Net Loss: The company reported a substantial net loss compared to the previous year, raising concerns about financial sustainability amid high expenditures.

5. Notable Q&A Insights

• Onapgo Demand and Supply: Management acknowledged strong demand for Onapgo but indicated that supply constraints could affect Q4 performance. They are prioritizing existing patients while working to resolve supply issues.
• Competitive Landscape: There are concerns about potential patient loss to competitors due to supply constraints, but management remains confident in Onapgo's long-term value and differentiation.
• Sales Force Expansion: Discussions around expanding the sales force for Zurzuvae are ongoing, but no specific timeline was provided.
• Acquisition Strategy: Supernus is open to pursuing additional acquisitions, particularly in CNS and women's health, leveraging the infrastructure developed through the Sage acquisition.

Overall, Supernus Pharmaceuticals reported strong revenue growth driven by key products but faces challenges related to supply constraints and rising operational costs. The company is optimistic about its future growth trajectory while navigating these hurdles.